Galectin Therapeutics Supports Investigational New Drug (IND) Application For Its Galectin Inhibitor GR-MD-02 In Metastatic Melanoma

Published: Jan 15, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORCROSS, Ga., Jan. 15, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Providence Portland Medical Center filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) on December 27, 2013 to study GR-MD-02 in combination with Yervoy® (ipilimumab) in a Phase 1B study of patients with metastatic melanoma. GR-MD-02 is Galectin Therapeutics' proprietary molecule that binds to and inhibits galectin proteins, predominantly galectin-3.

Help employers find you! Check out all the jobs and post your resume.

Back to news